Bisarro Dos Reis Mariana, Barros-Filho Mateus Camargo, Marchi Fábio Albuquerque, Beltrami Caroline Moraes, Kuasne Hellen, Pinto Clóvis Antônio Lopes, Ambatipudi Srikant, Herceg Zdenko, Kowalski Luiz Paulo, Rogatto Silvia Regina
International Research Center, CIPE, A.C. Camargo Cancer Center and National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, SP, Brazil.
Department of Urology, Faculty of Medicine, UNESP, São Paulo State University, Botucatu 18618-970, SP, Brazil.
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4089-4099. doi: 10.1210/jc.2017-00881.
Even though the majority of well-differentiated thyroid carcinoma (WDTC) is indolent, a number of cases display an aggressive behavior. Cumulative evidence suggests that the deregulation of DNA methylation has the potential to point out molecular markers associated with worse prognosis.
To identify a prognostic epigenetic signature in thyroid cancer.
Genome-wide DNA methylation assays (450k platform, Illumina) were performed in a cohort of 50 nonneoplastic thyroid tissues (NTs), 17 benign thyroid lesions (BTLs), and 74 thyroid carcinomas (60 papillary, 8 follicular, 2 Hürthle cell, 1 poorly differentiated, and 3 anaplastic). A prognostic classifier for WDTC was developed via diagonal linear discriminant analysis. The results were compared with The Cancer Genome Atlas (TCGA) database.
A specific epigenetic profile was detected according to each histological subtype. BTLs and follicular carcinomas showed a greater number of methylated CpG in comparison with NTs, whereas hypomethylation was predominant in papillary and undifferentiated carcinomas. A prognostic classifier based on 21 DNA methylation probes was able to predict poor outcome in patients with WDTC (sensitivity 63%, specificity 92% for internal data; sensitivity 64%, specificity 88% for TCGA data). High-risk score based on the classifier was considered an independent factor of poor outcome (Cox regression, P < 0.001).
The methylation profile of thyroid lesions exhibited a specific signature according to the histological subtype. A meaningful algorithm composed of 21 probes was capable of predicting the recurrence in WDTC.
尽管大多数高分化甲状腺癌(WDTC)生长缓慢,但仍有一些病例表现出侵袭性。累积证据表明,DNA甲基化失调有可能指出与预后较差相关的分子标志物。
在甲状腺癌中识别一种预后表观遗传特征。
对50例非肿瘤性甲状腺组织(NTs)、17例良性甲状腺病变(BTLs)和74例甲状腺癌(60例乳头状癌、8例滤泡状癌、2例许特莱细胞癌、1例低分化癌和3例未分化癌)进行全基因组DNA甲基化检测(Illumina 450k平台)。通过对角线性判别分析开发了WDTC的预后分类器。将结果与癌症基因组图谱(TCGA)数据库进行比较。
根据每种组织学亚型检测到特定的表观遗传特征。与NTs相比,BTLs和滤泡状癌显示出更多的甲基化CpG,而甲基化不足在乳头状癌和未分化癌中占主导。基于21个DNA甲基化探针的预后分类器能够预测WDTC患者的不良预后(内部数据的敏感性为63%,特异性为92%;TCGA数据的敏感性为64%,特异性为88%)。基于该分类器的高风险评分被认为是不良预后的独立因素(Cox回归,P<0.001)。
甲状腺病变的甲基化特征根据组织学亚型表现出特定的特征。一个由21个探针组成的有意义的算法能够预测WDTC的复发。